COMMUNIQUÉ DE PRESSE publié le 08/05/2024 à 12:30, il y a 4 mois 11 jours A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox NanoViricides reports NV-387 shows strong orthopoxvirus activity against Smallpox/Mpox via inhalation and skin transmission. Study highlights efficacy in lethal animal models, supporting clinical development potential NanoViricides NV-387 Clinical Development Orthopoxvirus Antiviral
BRÈVE publiée le 06/05/2024 à 12:35, il y a 4 mois 13 jours NanoViricides rapporte des résultats prometteurs pour le NV-387 dans le traitement de la grippe A NanoViricides NV-387 Grippe A Médicaments Antiviraux Grippe Aviaire H5N1
BRÈVE publiée le 06/05/2024 à 12:35, il y a 4 mois 13 jours NanoViricides Reports Promising Results for NV-387 in Treating Influenza A NanoViricides NV-387 Antiviral Drugs Influenza A H5N1 Bird Flu
COMMUNIQUÉ DE PRESSE publié le 06/05/2024 à 12:30, il y a 4 mois 13 jours A Novel Broad-Spectrum Antiviral with Activity Against Influenza A NanoViricides reports strong anti-influenza activity of NV-387, suggesting effectiveness against H5N1 bird flu virus. Results show superior performance to approved drugs. Further studies needed for confirmation NanoViricides NV-387 Anti-influenza H5N1 Drug
BRÈVE publiée le 30/04/2024 à 12:35, il y a 4 mois 19 jours NanoViricides Announces Successful Completion of Phase I Clinical Trial for NV-387 NanoViricides NV-387 Phase I Clinical Trial Antiviral Treatment RSV Infection
BRÈVE publiée le 30/04/2024 à 12:35, il y a 4 mois 19 jours NanoViricides annonce la réussite de l'essai clinique de phase I pour le NV-387 NanoViricides NV-387 Essai Clinique De Phase I Traitement Antiviral Infection Par Le VRS
COMMUNIQUÉ DE PRESSE publié le 30/04/2024 à 12:30, il y a 4 mois 19 jours NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon NanoViricides reports successful completion of Phase I Clinical Trial of NV-387, progresses towards Phase II discussion with physicians and experts for dosing protocol determination NanoViricides NV-387 Phase I Clinical Trial Phase II Discussion Antiviral Drug
COMMUNIQUÉ DE PRESSE publié le 15/02/2024 à 12:30, il y a 7 mois 4 jours NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon NanoViricides, Inc. files Quarterly Report on Form 10-Q with SEC, reports financial status and cash balance of $5.31 Million. Company makes strategic moves to improve liquidity and prepares for Phase II clinical trials Quarterly Report Clinical Trials Form 10-Q NanoViricides Inc. Financial Status
COMMUNIQUÉ DE PRESSE publié le 01/02/2024 à 12:20, il y a 7 mois 18 jours Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics NanoViricides, Inc. reports on the strong safety and tolerability of NV-CoV-2 oral drug products, showcasing their potential for long-term success and broad-spectrum antiviral capabilities, including against RSV and Smallpox-like viruses NV-387 NanoViricides Inc Antiviral Drugs Nanoviricides Platform COVID Therapeutics
COMMUNIQUÉ DE PRESSE publié le 29/01/2024 à 12:30, il y a 7 mois 21 jours Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found NanoViricides, Inc. successfully completes Phase 1a/1b Clinical Trial of NV-CoV-2, reporting excellent safety and broad-spectrum antiviral activity of NV-387 against various respiratory viruses including Coronaviruses and RSV NV-387 NanoViricides Inc NV-CoV-2 Phase 1a/1b Clinical Trial Antiviral Therapy
Publié le 19/09/2024 à 17:45, il y a 12 heures 49 minutes Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Publié le 19/09/2024 à 17:45, il y a 12 heures 49 minutes Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Publié le 19/09/2024 à 17:45, il y a 12 heures 49 minutes Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Publié le 20/09/2024 à 02:00, il y a 4 heures 34 minutes Academy of Math and Science Celebrates Hispanic Heritage Month
Publié le 19/09/2024 à 23:15, il y a 7 heures 19 minutes Cypher Metaverse Inc. Announces Second Closing of Financing
Publié le 19/09/2024 à 23:00, il y a 7 heures 34 minutes WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Publié le 19/09/2024 à 23:00, il y a 7 heures 34 minutes Cerrado Files NI 43-101 Preliminary Economic Assessment Technical Report and Mineral Resource Estimate for The Minera Don Nicolas Mine in Santa Cruz, Argentina
Publié le 20/09/2024 à 06:26, il y a 8 minutes Original-Research: www.warimpex.com (von East Value Research GmbH ):
Publié le 20/09/2024 à 05:15, il y a 1 heure 19 minutes Alibaba Cloud Empowers Customers and Partners with its Proven Large Models and High-Performance Infrastructure
Publié le 19/09/2024 à 21:09, il y a 9 heures 24 minutes EQS-Adhoc: Mercedes-Benz Group AG adjusts full-year guidance for the year 2024 based on current market outlook
Publié le 19/09/2024 à 18:44, il y a 11 heures 50 minutes Fuller, Smith & Turner PLC: Transaction in own shares
Publié le 19/09/2024 à 18:03, il y a 12 heures 31 minutes Funding Circle Plc: POS-Transaction in Own Shares